Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Montes de Oca

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Checkpoint Inhibition Before Haploidentical Transplantation in Relapsed or Refractory Hodgkin Lymphoma Patients Is Associated With Higher PFS Without Increased Toxicities

Hematological Oncology

English

Related publications

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

English

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Hematological Oncology

English

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

Clinical Lymphoma, Myeloma and Leukemia

English

A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

British Journal of Haematology

Hematology

2016

English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

American Journal of Hematology

Hematology

2018

English

Safety and Clinical Activity of Temsirolimus in Combination With Rituximab and Dhap in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma-Report of the Prospective, Multicenter Phase Ii Storm Trial

Hematological Oncology

English

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology

English

Phase Ii Study of Durvalumab (Anti-Pd-L1) Combined With Either R-Chop or Lenalidomide and R-Chop in Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Accept: A Phase Ib/Ii Combination of Acalabrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-Chop) for Patients With Diffuse Large B-Cell Lymphoma (Dlbcl)

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Montes de Oca

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Checkpoint Inhibition Before Haploidentical Transplantation in Relapsed or Refractory Hodgkin Lymphoma Patients Is Associated With Higher PFS Without Increased Toxicities

Related publications

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

Safety and Clinical Activity of Temsirolimus in Combination With Rituximab and Dhap in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma-Report of the Prospective, Multicenter Phase Ii Storm Trial

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Phase Ii Study of Durvalumab (Anti-Pd-L1) Combined With Either R-Chop or Lenalidomide and R-Chop in Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma

Accept: A Phase Ib/Ii Combination of Acalabrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-Chop) for Patients With Diffuse Large B-Cell Lymphoma (Dlbcl)